Powered for statistical significance
Cohorts powered with more than 5,000 patients for many diseases or clinical features. Control groups of up to 15,000 healthy individuals.
Select for therapeutic area, geographic location, or ethnic background. Cohorts contain genotypic data enriched with deep phenotypic data, and are statistically powered to distinguish signal from noise.
Europe, Asia, N. America
In this webinar experts from across the pharma field discuss potential new targets and approaches for NASH therapy, and where the field will go in the near future.Read More
With the recent acquisition of Genomics Medicine Ireland (GMI, in Dublin), WuXi NextCODE is realizing the vision of turning advancements in genomics into improvements in drug discovery and ultimately population health, providing benefit to patients around the world.Read More
With the announced $400 million investment from global investors including the Irish sovereign fund, WuXi NextCODE announced that GMI would whole genome sequence and collect detailed medical data on 400,000 Irish volunteers covering 60 major diseases, partnering with life sciences companies to analyse the data for insights.Read More